New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms
Article Properties
-
DOI (url)
-
Publication Date2022/05/07
-
Indian UGC (journal)
-
Refrences101
-
Citations8
-
Feng Yin
-
Zi-Hao Wu
-
Jin-Ping Lai
Cite
Yin, Feng, et al. “New Insights in Diagnosis and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms”. World Journal of Gastroenterology, vol. 28, no. 17, 2022, pp. 1751-67, https://doi.org/10.3748/wjg.v28.i17.1751.
Yin, F., Wu, Z.-H., & Lai, J.-P. (2022). New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. World Journal of Gastroenterology, 28(17), 1751-1767. https://doi.org/10.3748/wjg.v28.i17.1751
Yin, Feng, Zi-Hao Wu, and Jin-Ping Lai. “New Insights in Diagnosis and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms”. World Journal of Gastroenterology 28, no. 17 (2022): 1751-67. https://doi.org/10.3748/wjg.v28.i17.1751.
Yin F, Wu ZH, Lai JP. New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. World Journal of Gastroenterology. 2022;28(17):1751-67.
Journal Categories
Medicine
Internal medicine
Specialties of internal medicine
Diseases of the digestive system
Gastroenterology
Medicine
Medicine (General)
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
Pembrolizumab for the treatment of programmed death–ligand 1‒positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE‐028 study | Cancer |
| 78 | 2020 |
Immune Checkpoint Inhibitors in the Treatment of Patients with Neuroendocrine Neoplasia | Oncology Research and Treatment |
| 61 | 2018 |
| 10.1016/S1470-2045(16)30364-3 | ||||
Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance | Annual Review of Pathology: Mechanisms of Disease |
| 928 | 2021 |
| 10.1016/S0140-6736(15)00817-X |
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Risk factors for positive resection margins after endoscopic resection for gastrointestinal neuroendocrine tumors | Surgical Endoscopy |
| 2024 | |
Risk factors, prognostic factors, and nomograms for distant metastases in patients with gastroenteropancreatic neuroendocrine tumors: a population-based study | Frontiers in Endocrinology |
| 2024 | |
| Risk of metastasis and survival in patients undergoing different treatment strategies with T1 colonic neuroendocrine tumors | Journal of Endocrinological Investigation |
| 2023 | |
| Surgical management of pancreatic neuroendocrine neoplasms | Laparoscopic, Endoscopic and Robotic Surgery | 2023 | ||
Early-onset pancreatic neuroendocrine neoplasms: A distinct disease with improved survival compared with old individuals | Frontiers in Endocrinology |
| 1 | 2023 |
Citations Analysis
The category
Medicine: Medicine (General) 6
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Molecular factors, diagnosis and management of gastrointestinal tract neuroendocrine tumors: An update and was published in 2022. The most recent citation comes from a 2024 study titled Risk factors for positive resection margins after endoscopic resection for gastrointestinal neuroendocrine tumors. This article reached its peak citation in 2023, with 5 citations. It has been cited in 7 different journals, 42% of which are open access. Among related journals, the Frontiers in Endocrinology cited this research the most, with 2 citations. The chart below illustrates the annual citation trends for this article.